Ability Apixaban Investigation To Lower the Incidence of Thromboembolic Events In Cancer Therapy Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 13 years ago on Monday, May 16, 2011, according to the United State Patent & Trademark Office
Word Mark Ability Apixaban Investigation to Lower the Incidence of Thromboembolic Events in Cancer Therapy
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77085410
Status Date Monday, May 16, 2011
Filing Date Monday, May 16, 2011
Attorney Tanya Fickenscher Leonard

Correspondent

Tanya Fickenscher Leonard
Bristol-Myers Squibb Company
345 Park Avenue
New York NY 10154

Case File Statements

Disclaimer with Predetermined Text "Apixaban Investigation to Lower the Incidence of Thromboembolic Events in Cancer Therapy"
Goods & Services Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations and/or diagnostic imaging agents for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Tuesday, January 23, 2007
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.